We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biomarker Identified for Multiple Myeloma

By LabMedica International staff writers
Posted on 02 Jan 2013
A molecule that typically prevents cell death has been identified as a potential biomarker to identify an incurable form of cancer in the bone marrow. More...


Most people who develop this cancer, known as multiple myeloma (MM), have no clearly identifiable risk factors for the disease except for being older than 50 years of age, male and obese, which may predispose individuals to the cancer.

Scientists at the Agency for Science, Technology and Research (A*STAR, Singapore) discovered that a protein called Fas apoptosis inhibitory molecule (FAIM) can affect the activation of alpha serine/threonine-protein kinase (AKT), an important enzyme required for cancer cell proliferation. The team used various techniques including cell culture, Western blot analysis of protein expression, transfection, and cell viability assays.

They also investigated the messenger ribonucleic acid (mRNA) expression of FAIM in normal and malignant plasma cell samples from 15 healthy individuals and 147 patients with various plasma cell neoplasms. The latter include 22 cases of monoclonal gammopathy of undetermined significance, 24 smoldering MM and 101 symptomatic MM and of the 101MM cases, 72 were newly diagnosed, and 29 were relapsed cases. The FAIM expression level was found to be significantly increased in MM patients compared with normal individuals. More importantly, when compared with asymptomatic but malignant condition such as smoldering MM, the expression level of FAIM was again found to be higher for MM. Therefore, FAIM appears to be aberrantly upregulated in MM.

Lam Kong-Peng, PhD, the professor who led the study said, "We found that this protein was present at higher levels in the plasma cells of these patients as compared to normal individuals, and that higher levels of FAIM correlated to poorer survival outcomes of patients. This is an important breakthrough as it not only identifies FAIM as a useful biomarker of multiple myeloma patients, but also as a good target that drugs can be developed for, in order to get rid of the cancer cells." The study was published on December 4, 2012, in the journal Leukemia.

Related Links:

Singapore Agency for Science, Technology and Research



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.